Sanofi Gross Profit 2010-2023 | SNY

Sanofi annual/quarterly gross profit history and growth rate from 2010 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Sanofi gross profit for the quarter ending December 31, 2023 was $8.779B, a 9.79% increase year-over-year.
  • Sanofi gross profit for the twelve months ending December 31, 2023 was $34.859B, a 4.39% increase year-over-year.
  • Sanofi annual gross profit for 2023 was $34.859B, a 4.39% increase from 2022.
  • Sanofi annual gross profit for 2022 was $33.393B, a 4.85% increase from 2021.
  • Sanofi annual gross profit for 2021 was $31.849B, a 10.59% increase from 2020.
Sanofi Annual Gross Profit
(Millions of US $)
2023 $34,859
2022 $33,393
2021 $31,849
2020 $28,800
2019 $28,734
2018 $28,630
2017 $27,797
2016 $26,565
2015 $26,585
2014 $30,680
2013 $29,642
2012 $31,945
2011 $33,644
2010 $30,964
2009 $31,893
Sanofi Quarterly Gross Profit
(Millions of US $)
2023-12-31 $8,779
2023-09-30 $9,640
2023-06-30 $8,084
2023-03-31 $8,355
2022-12-31 $7,996
2022-09-30 $9,374
2022-06-30 $7,973
2022-03-31 $8,050
2021-09-30 $8,951
2021-06-30
2021-03-31 $7,477
2020-09-30 $7,835
2020-03-31 $7,117
2019-09-30 $7,547
2019-03-31 $6,923
2018-03-31 $6,860
2017-12-31 $6,943
2017-09-30 $7,686
2017-06-30 $6,654
2017-03-31 $6,514
2016-12-31 $6,708
2016-09-30 $7,275
2016-06-30 $6,535
2016-03-31 $6,047
2015-09-30 $7,434
2015-06-30 $7,216
2014-06-30 $7,597
2013-06-30 $7,066
2012-06-30 $8,204
2012-03-31 $7,803
2011-12-31 $7,948
2011-09-30 $7,988
2011-06-30 $7,960
2011-03-31 $8,191
2010-12-31 $6,923
2010-09-30 $7,826
2010-06-30 $8,001
2010-03-31 $6,934
2009-12-31 $7,000
2009-09-30 $8,023
2009-06-30 $8,059
2009-03-31 $6,720
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $122.796B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $767.386B 110.91
Novo Nordisk (NVO) Denmark $610.484B 46.91
Johnson & Johnson (JNJ) United States $353.710B 14.05
Merck (MRK) United States $327.973B 59.67
AbbVie (ABBV) United States $277.347B 14.33
AstraZeneca (AZN) United Kingdom $243.511B 21.17
Novartis AG (NVS) Switzerland $205.483B 14.57
Pfizer (PFE) United States $163.651B 20.34
Innoviva (INVA) United States $0.985B 6.92